3.0.0 6576 2023-01-11T13:41:55Z 2023-01-11T13:41:55Z House HR 2018-07-26 115 [Congressional Record Volume 164, Number 126 (Thursday, July 26, 2018)]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. SCHAKOWSKY:H.R. 6576.Congress has the power to enact this legislation pursuantto the following:Pursuant to Article I, Section 8, Clause 3 of the UnitedStates Constitution[Page H7726]]]> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2018-07-27T17:45:56Z Referred to 2018-07-26T13:03:25Z Drug-Price Transparency in Communications Act 115 2157 S 2017-11-16 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Identical bill CRS 2018-07-27 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2018-07-26 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2018-07-26 Introduced in House IntroReferral Intro-H 9 Library of Congress 2018-07-26 Introduced in House IntroReferral 1000 9 Library of Congress S001145 Rep. Schakowsky, Janice D. [D-IL-9] JANICE SCHAKOWSKY D IL D. 9 N Health Drug safety, medical device, and laboratory regulation Licensing and registrations Marketing and advertising Health 00 2018-07-26 Introduced in House 2019-08-20T19:52:14Z Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.

]]> Drug-Price Transparency in Communications Act Display Title Drug-Price Transparency in Communications Act Official Title as Introduced To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug. Introduced in House IH Short Titles as Introduced Drug-Price Transparency in Communications Act Introduced in House 2018-07-26T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-115hr6576ih/xml/BILLS-115hr6576ih.xml 2018-07-27 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.